Phenotype of hepatic infiltrates and hepatic lymph nodes of lambs primarily and challenge infected with Fasciola hepatica, with and without triclabendazole treatment.
The phenotype of the hepatic inflammatory infiltrate and hepatic lymph nodes (HLN) was analysed in lambs primarily and challenge infected with Fasciola hepatica. Group 1 was primarily and challenge infected with two doses of 200 metacercariae (mc) each and was non-treated. Trickle infection was administered to five groups: group 2 was challenge infected and non-treated; group 3 was primarily infected and non-treated; group 4 was primarily infected and treated with triclabendazole (TCBZ) at 12 weeks postinfection (wpi); group 5 was treated at 4 wpi and challenge infected and group 6 was treated at 12 wpi and challenge infected. An uninfected group was used as the control. The distribution of T cell subpopulations (CD3, CD4 and CD8), and B cells (CD79alpha, IgM, IgG) was analysed. The hepatic inflammatory infiltrate was represented mainly by CD3 and CD4 T cells, and B cells (CD79alpha, IgG). These infiltrates were more severe (P < 0.05) in primarily (group 3) or challenge (groups 2, 5 and 6) trickle infected lambs than in the group single challenge infected (group 1). Cellular changes in HLN consisted in an increase of CD4 over CD8 T cells and an increase of B cells and IgG+ plasma cells, and they were more severe in primarily and challenge trickle infected groups than in the group infected with two larger doses of mc, although significant differences were not found with respect to all challenge trickle infected groups. The strong local cellular and humoral immune responses did not protect against subsequent infections, neither in non-treated lambs (group 2) nor in lambs treated with TCBZ at 4 wpi (group 5) or 12 wpi (group 6).
Pérez
José
J
Departamento de Anatomía y Anatomía Patológica Comparadas, Edificio de Sanidad Animal, Campus de Rabanales, Ctra, Madrid-Cádiz, Km 396, 14014 Córdoba, Spain. an1pearj@uco.es
Ortega
Joaquín
J
Bravo
Ana
A
Díez-Baños
Pablo
P
Morrondo
Patrocinio
P
Moreno
Teodoro
T
Martínez-Moreno
Alvaro
A
D000818:Animals; D000831:Animals, Newborn; D000871:Anthelmintics / Q000627:therapeutic use*; D001562:Benzimidazoles / Q000627:therapeutic use*; D005210:Fasciola hepatica / Q000276:immunology* / Q000472:pathogenicity; D005211:Fascioliasis / Q000188:drug therapy / Q000276:immunology / Q000662:veterinary*; D007150:Immunohistochemistry / Q000662:veterinary; D008099:Liver / Q000469:parasitology / Q000473:pathology; D008198:Lymph Nodes / Q000469:parasitology / Q000473:pathology; D016131:Lymphocyte Subsets; D010641:Phenotype; D012756:Sheep; D012757:Sheep Diseases / Q000188:drug therapy / Q000276:immunology*; D000077682:Triclabendazole
D000871:Anthelmintics; D001562:Benzimidazoles; D000077682:Triclabendazole